Alliance Global Partners analyst Ben Haynor lowered the firm’s price target on DarioHealth to $5.45 from $5.90 and keeps a Buy rating on the shares. The company announced preliminary Q2 revenue below expectations but its revenue mix was not disclosed, making it difficult to draw conclusions, the analyst tells investors in a research note. Based on the preliminary Q2 results and the revised Aetna timeline, the firm reduced estimates.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on DRIO:
- DarioHealth price target lowered to $6 from $9 at Stifel
- DarioHealth sees Q2 revenue $6.0M-$6.15M, consensus $6.73M
- DarioHealth announces agreement with large regional health plan
- DarioHealth announces new full suit employer contract
- DarioHealth files to sell 6.58M shares of common stock for holders